Ciudad Autónoma de Buenos Aires, Argentina

Martin Luong

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 13.0

ph-index = 1


Company Filing History:


Years Active: 2024

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Martin Luong: Innovator in Neurodegenerative Disease Treatment

Introduction

Martin Luong is a notable inventor based in Ciudad Autónoma de Buenos Aires, Argentina. He has made significant contributions to the field of neurodegenerative diseases through his innovative research and patenting efforts. His work focuses on enhancing the delivery of bioactive drugs into the central nervous system.

Latest Patents

Martin Luong holds a patent for a "Chemically coupled transporter for low-hydrophobicity bioactive drugs into the central nervous system." This patent describes a compound that includes a modified tetracycline derivative, which is covalently linked to a low-hydrophobicity bioactive molecule. This innovative approach aims to improve treatment options for neurodegenerative diseases. He has 1 patent to his name.

Career Highlights

Throughout his career, Martin has worked with various organizations, including Skybio LLC and the National Scientific and Technical Research Council (CONICET). His experience in these institutions has allowed him to develop and refine his research in the field of drug delivery systems.

Collaborations

Martin has collaborated with esteemed colleagues such as Oscar José Varela and Rosana Nieves Chehín. These partnerships have contributed to the advancement of his research and the successful development of his patented technologies.

Conclusion

Martin Luong is a dedicated inventor whose work in the field of neurodegenerative diseases has the potential to make a significant impact on treatment methodologies. His innovative approaches and collaborations highlight his commitment to advancing medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…